At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,796 enrolled
Drug / intervention
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (20VPNC) WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE (SIIV) IN ADULTS ≥65 YEARS OF AGE
In Brief
A Phase 3 clinical trial evaluating Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, and 1 other intervention for Pneumococcal Disease. Completed, enrolled 1,796 participants across 63 sites.
Detailed Summary
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedAug 26, 2020
Enrollment StartSep 1, 2020
Primary CompletionJun 29, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.9 years ago
Interventions
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)biological
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Salineother
Normal saline for injection
Influenza vaccinebiological
Seasonal inactivated influenza vaccine (SIIV)